Literature DB >> 28612200

Diagnosis and staging of pancreatic ductal adenocarcinoma.

C Guillén-Ponce1, J Blázquez2, I González3, E de-Madaria4, J Montáns5, A Carrato6.   

Abstract

The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC patients are diagnosed in advanced stages. The signs and symptoms of the disease, except for jaundice, are non-specific. Thus, the current challenge is to identify earlier those individuals for whom specific screening tools and specific treatments would be beneficial. On the basis of the recommendations of the group of experts of multiple medical specialties of the GALLgo Project, the patients with PDAC should be managed by a multidisciplinary team to assess the personal and family history, the best diagnostic and staging procedures and consider all important aspects for treatment decisions. In this article, the group of experts proposes strategies to shorten the diagnosis times in PDAC patients.

Entities:  

Keywords:  Diagnosis; Pancreatic ductal adenocarcinoma; Staging

Mesh:

Year:  2017        PMID: 28612200     DOI: 10.1007/s12094-017-1681-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  27 in total

1.  Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

Authors:  Naru Kondo; Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Yasushi Hashimoto; Akira Nakashima; Ryutaro Sakabe; Norifumi Shigemoto; Yasushi Kato; Hiroki Ohge; Taijiro Sueda
Journal:  Ann Surg Oncol       Date:  2010-03-25       Impact factor: 5.344

Review 2.  Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.

Authors:  Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2013-02-23       Impact factor: 5.344

3.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

4.  Clinical and pathologic features of familial pancreatic cancer.

Authors:  Jeremy L Humphris; Amber L Johns; Skye H Simpson; Mark J Cowley; Marina Pajic; David K Chang; Adnan M Nagrial; Venessa T Chin; Lorraine A Chantrill; Mark Pinese; R Scott Mead; Anthony J Gill; Jaswinder S Samra; James G Kench; Elizabeth A Musgrove; Katherine M Tucker; Allan D Spigelman; Nic Waddell; Sean M Grimmond; Andrew V Biankin
Journal:  Cancer       Date:  2014-10-14       Impact factor: 6.860

5.  Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus.

Authors:  Phil A Hart; Pratima Kamada; Kari G Rabe; Sunil Srinivasan; Ananda Basu; Gaurav Aggarwal; Suresh T Chari
Journal:  Pancreas       Date:  2011-07       Impact factor: 3.327

6.  Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis.

Authors:  K Nishida; T Kaneko; M Yoneda; S Nakagawa; T Ishikawa; E Yamane; B Nishioka; Y Miyamoto; H Takano; T Yoshikawa; M Kondo
Journal:  J Surg Oncol       Date:  1999-07       Impact factor: 3.454

Review 7.  Addressing the challenges of pancreatic cancer: future directions for improving outcomes.

Authors:  Manuel Hidalgo; Stefano Cascinu; Jörg Kleeff; Roberto Labianca; J-Matthias Löhr; John Neoptolemos; Francisco X Real; Jean-Luc Van Laethem; Volker Heinemann
Journal:  Pancreatology       Date:  2014-10-17       Impact factor: 3.996

Review 8.  Imaging of pancreatic adenocarcinoma: update on staging/resectability.

Authors:  Eric P Tamm; Aparna Balachandran; Priya R Bhosale; Matthew H Katz; Jason B Fleming; Jeffrey H Lee; Gauri R Varadhachary
Journal:  Radiol Clin North Am       Date:  2012-04-06       Impact factor: 2.303

9.  Previous disability as a predictor of outcome in a geriatric rehabilitation unit.

Authors:  E Valderrama-Gama; J Damián; E Guallar; L Rodríguez-Mañas
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1998-09       Impact factor: 6.053

10.  When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery.

Authors:  Horacio J Asbun; Kevin Conlon; Laureano Fernandez-Cruz; Helmut Friess; Shailesh V Shrikhande; Mustapha Adham; Claudio Bassi; Maximilian Bockhorn; Markus Büchler; Richard M Charnley; Christos Dervenis; Abe Fingerhutt; Dirk J Gouma; Werner Hartwig; Clem Imrie; Jakob R Izbicki; Keith D Lillemoe; Miroslav Milicevic; Marco Montorsi; John P Neoptolemos; Aken A Sandberg; Michael Sarr; Charles Vollmer; Charles J Yeo; L William Traverso
Journal:  Surgery       Date:  2014-01-02       Impact factor: 3.982

View more
  4 in total

1.  LncRNA-BLACAT1 Facilitates Proliferation, Migration and Aerobic Glycolysis of Pancreatic Cancer Cells by Repressing CDKN1C via EZH2-Induced H3K27me3.

Authors:  Xin Zhou; Wei Gao; Huanhuan Hua; Zhimin Ji
Journal:  Front Oncol       Date:  2020-09-23       Impact factor: 6.244

2.  Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer.

Authors:  Walid L Shaib; Katerina Zakka; Asser A Shahin; Fares Yared; Jeffrey M Switchenko; Christina Wu; Mehmet Akce; Olatunji B Alese; Pretesh R Patel; Mark Mcdonald; Bassel F El-Rayes
Journal:  Pancreas       Date:  2020-07       Impact factor: 3.327

3.  Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients.

Authors:  Jie Ju; Leonoor V Wismans; Dana A M Mustafa; Marcel J T Reinders; Casper H J van Eijck; Andrew P Stubbs; Yunlei Li
Journal:  iScience       Date:  2021-11-10

4.  Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model.

Authors:  Sajad Shafiekhani; Hojat Dehghanbanadaki; Azam Sadat Fatemi; Sara Rahbar; Jamshid Hadjati; Amir Homayoun Jafari
Journal:  BMC Cancer       Date:  2021-11-15       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.